Pyxis Oncology Inc. (PYXS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Pyxis Oncology Inc.

    NASDAQ: PYXS · Real-Time Price · USD
    2.57
    0.32 (14.22%)
    At close: Oct 03, 2025, 3:59 PM
    2.57
    0.00%
    After-hours: Oct 03, 2025, 07:45 PM EDT

    Pyxis Oncology Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 16.15M n/a n/a n/a
    Cost of Revenue
    		 475K 2M 1.84M 1.25M
    Gross Profit
    		 15.67M -2M -1.84M -1.25M
    Operating Income
    		 -89.46M -82.2M -123.48M -69.72M
    Interest Income
    		 7.04M 6.63M 2.76M 23K
    Pretax Income
    		 -79.5M -73.79M -120.72M -75.97M
    Net Income
    		 -77.33M -73.79M -117.95M -81.54M
    Selling & General & Admin
    		 25.42M 32.61M 37.35M 18.66M
    Research & Development
    		 58.75M 47.89M 86.13M 51.05M
    Other Expenses
    		 20.96M n/a n/a 181K
    Operating Expenses
    		 105.13M 82.2M 123.48M 69.72M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 105.61M 82.2M 123.48M 69.72M
    Income Tax Expense
    		 -2.16M n/a -2.76M 5.56M
    Shares Outstanding (Basic)
    		 58.45M 39.9M 33.03M 32.22M
    Shares Outstanding (Diluted)
    		 58.45M 39.9M 33.03M 32.22M
    EPS (Basic)
    		 -1.32 -1.85 -3.57 -2.53
    EPS (Diluted)
    		 -1.32 -1.85 -3.57 -2.53
    EBITDA
    		 -65.51M -78.49M -122.77M -69.07M
    EBIT
    		 -68.5M -80.42M -123.48M -69.72M
    Depreciation & Amortization
    		 2.98M 2M 1.84M 1.25M

    Add to Watchlist